We are live on ! Find out more
PBM

Propel Bio Management Portfolio holdings

AUM $191M
1-Year Est. Return 102.42%
This Fund
S&P 500
This Quarter Est. Return
+40.62%
1 Year Est. Return
+102.42%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$191M
AUM Growth
+$32.4M
Cap. Flow
-$2.57M
Cap. Flow %
-1.34%
Top 10 Hldgs %
68.15%
Holding
41
New
3
Increased
12
Reduced
10
Closed
12

Top Buys

Rank Stock Value
1
MIST icon
Milestone Pharmaceuticals
MIST
+$5.29M
2
ARTV
Artiva Biotherapeutics
ARTV
+$5.01M
3
SCYX icon
SCYNEXIS
SCYX
+$3.37M
4
AQST icon
Aquestive Therapeutics
AQST
+$3.08M
5
PALI icon
Palisade Bio
PALI
+$2.89M

Top Sells

Rank Stock Value
1
VOR icon
Vor Biopharma
VOR
+$5.59M
2
VRDN icon
Viridian Therapeutics
VRDN
+$4.09M
3
OCS icon
Oculis Holding
OCS
+$3.28M
4
TRVI icon
Trevi Therapeutics
TRVI
+$2.65M
5
CHRS icon
Coherus Oncology
CHRS
+$2.41M

Sector Composition

Rank Sector Weight
1 Healthcare 83.84%
2 Energy 16.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PAGP icon
1
Plains GP Holdings
PAGP
$5.54B
$30.9M 16.16%
1,272,360
– –
ACHV icon
2
Achieve Life Sciences
ACHV
$834M
$26.3M 13.79%
4,034,018
+247,593
+7% +$1.18M
CORT icon
3
Corcept Therapeutics
CORT
$12.3B
$11.9M 6.21%
136,499
-11,329
-8% -$684K
PHAT icon
4
Phathom Pharmaceuticals
PHAT
$743M
$11.4M 5.96%
1,050,358
+209,086
+25% +$2.39M
DCTH icon
5
Delcath Systems
DCTH
$567M
$11M 5.74%
871,460
-108,238
-11% -$1.2M
MIST icon
6
Milestone Pharmaceuticals
MIST
$144M
$9.96M 5.21%
7,429,590
+3,311,269
+80% +$5.29M
CMPS
7
Compass Pathways
CMPS
$1.9B
$8.11M 4.24%
573,086
-168,963
-23% -$1.71M
KYTX icon
8
Kyverna Therapeutics
KYTX
$518M
$7.87M 4.12%
883,198
+238,777
+37% +$2.12M
ARTV
9
Artiva Biotherapeutics
ARTV
$542M
$6.76M 3.54%
696,436
+550,067
+376% +$5.01M
ABEO icon
10
Abeona Therapeutics
ABEO
$339M
$6.08M 3.18%
983,070
-346,829
-26% -$1.9M
AQST icon
11
Aquestive Therapeutics
AQST
$630M
$6M 3.14%
1,442,397
+731,409
+103% +$3.08M
PALI icon
12
Palisade Bio
PALI
$349M
$5.4M 2.82%
2,582,388
+1,467,388
+132% +$2.89M
IMUX icon
13
Immunic
IMUX
$210M
$5M 2.61%
325,022
+90,544
+39% +$1.12M
IVA
14
Inventiva
IVA
$1.11B
$4.84M 2.53%
1,281,212
+556,534
+77% +$2.67M
SABS icon
15
SAB Biotherapeutics
SABS
$345M
$4.2M 2.2%
1,076,578
+63,788
+6% +$237K
OBIO icon
16
Orchestra BioMed
OBIO
$312M
$3.87M 2.02%
896,701
– –
CLDX icon
17
Celldex Therapeutics
CLDX
$3.07B
$3.86M 2.02%
103,695
-27,669
-21% -$894K
ZVRA icon
18
Zevra Therapeutics
ZVRA
$687M
$3.64M 1.9%
253,544
-28,874
-10% -$321K
OCUL icon
19
Ocular Therapeutix
OCUL
$2.28B
$3.52M 1.84%
357,966
-24,409
-6% -$221K
FDMT icon
20
4D Molecular Therapeutics
FDMT
$810M
$3.36M 1.76%
252,654
-127,766
-34% -$1.24M
OVID icon
21
Ovid Therapeutics
OVID
$547M
$3M 1.57%
1,115,538
+194,081
+21% +$501K
EYPT icon
22
EyePoint Inc
EYPT
$386M
$2.74M 1.43%
191,745
-24,080
-11% -$322K
UPB
23
Upstream Bio Inc
UPB
$366M
$2.42M 1.27%
350,389
+8,610
+3% +$72.1K
SCYX icon
24
SCYNEXIS
SCYX
$53.6M
$2.21M 1.16%
+543,478
New +$3.37M
SLN
25
Silence Therapeutics
SLN
$834M
$2.11M 1.1%
+191,733
New +$1.35M
1
2

Similar funds

CFG
Capital Financial Group Greenwood Village, Colorado $191M AUM
MWM
Magnolia Wealth Management Dothan, Alabama $191M AUM 17.58% 1-Year Est. Return
ALWM
Andrews Lucia Wealth Management Danville, California $191M AUM 24.94% 1-Year Est. Return
PFA
Pillar Financial Advisors Louisville, Kentucky $191M AUM 21.21% 1-Year Est. Return
LKWM
Lee-Kelleher Wealth Management Fulton, Maryland $191M AUM 28.48% 1-Year Est. Return
NWM
Navigoe Wealth Management Redondo Beach, California $191M AUM 25.21% 1-Year Est. Return
AA
Atmos Advisory Pittsburgh, Pennsylvania $191M AUM 12.84% 1-Year Est. Return
MCA
Martin Capital Advisors San Antonio, Texas $191M AUM 42.42% 1-Year Est. Return

Propel Bio Management's Q2 2026 Portfolio in Review

As of Q2 2026, Propel Bio Management held 41 positions worth $191M, up 20% from $159M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Propel Bio Management's Q2 2026 filing shows 3 new, 12 increased, 10 reduced and 12 closed positions. Its largest new stake was SCYNEXIS: 543,478 shares worth $2.21M. The largest sale was Vor Biopharma, an estimated $5.59M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 81% a quarter earlier, followed by Energy.

  • Propel Bio Management's largest Q2 2026 buy was SCYNEXIS: 543,478 shares worth $2.21M.
  • Propel Bio Management added most to Milestone Pharmaceuticals in Q2 2026, an estimated $5.29M increase.
  • Propel Bio Management's biggest Q2 2026 reduction was Abeona Therapeutics, cutting an estimated $1.9M.
  • Propel Bio Management fully exited Vor Biopharma in Q2 2026, selling an estimated $5.59M.
  • Propel Bio Management's ten largest holdings make up 68% of its $191M portfolio in Q2 2026.
  • Propel Bio Management opened 3 new positions and closed 12 in Q2 2026.
  • Propel Bio Management's portfolio value rose 20% quarter-over-quarter to $191M.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.